CL2019003613A1 - Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos. - Google Patents

Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.

Info

Publication number
CL2019003613A1
CL2019003613A1 CL2019003613A CL2019003613A CL2019003613A1 CL 2019003613 A1 CL2019003613 A1 CL 2019003613A1 CL 2019003613 A CL2019003613 A CL 2019003613A CL 2019003613 A CL2019003613 A CL 2019003613A CL 2019003613 A1 CL2019003613 A1 CL 2019003613A1
Authority
CL
Chile
Prior art keywords
antibodies
bispecific antibodies
manufacture
therapeutic use
bispecific
Prior art date
Application number
CL2019003613A
Other languages
English (en)
Inventor
Michael Otto Bardroff
Tina Buch
Christian Graf
Daniel Heitmann
Thomas Jostock
Hans-Peter Knopf
Rolf Koheler
Jiri Kovarik
Stephen John Oliver
Dhavalkumar Patel
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019003613A1 publication Critical patent/CL2019003613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCIÓN SE REFIERE A ANTICUERPOS MONOCLONALES BIESPECÍFICOS BIVALENTES (BBMAB) O SUS VARIANTES, Y A MÉTODOS DE FABRICACIÓN DE DICHOS ANTICUERPOS MEDIANTE LA COEXPRESIÓN DE DERIVADOS MUTADOS FC MODIFICADOS, DE DOS ANTICUERPOS MONOCLONALES DIFERENTES, EN LÍNEAS CELULARES DE MAMÍFEROS.
CL2019003613A 2017-06-12 2019-12-10 Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos. CL2019003613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762518090P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
CL2019003613A1 true CL2019003613A1 (es) 2020-07-03

Family

ID=62948274

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003613A CL2019003613A1 (es) 2017-06-12 2019-12-10 Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.

Country Status (25)

Country Link
US (2) US20190002589A1 (es)
EP (1) EP3638692A1 (es)
JP (2) JP7106234B2 (es)
KR (2) KR102633368B1 (es)
CN (1) CN110730788A (es)
AR (1) AR112419A1 (es)
AU (2) AU2018284303B2 (es)
BR (1) BR112019025904A2 (es)
CA (1) CA3061097A1 (es)
CL (1) CL2019003613A1 (es)
CO (1) CO2019013838A2 (es)
CR (1) CR20190558A (es)
CU (1) CU20190100A7 (es)
EA (1) EA201992670A1 (es)
EC (1) ECSP19087580A (es)
IL (1) IL271179A (es)
JO (1) JOP20190283B1 (es)
MA (1) MA49394A (es)
MX (1) MX2019015021A (es)
PE (1) PE20200384A1 (es)
SG (1) SG10201913536TA (es)
TW (1) TWI826377B (es)
UY (1) UY37758A (es)
WO (1) WO2018229612A1 (es)
ZA (1) ZA201906757B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
KR20180069839A (ko) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
AU2018422406A1 (en) * 2018-05-09 2020-11-12 Novartis Ag Use of canakinumab
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
CN115066258A (zh) * 2020-02-28 2022-09-16 上海药明生物技术有限公司 双特异性抗体的纯化
JP2023549257A (ja) * 2020-11-18 2023-11-22 ノバルティス アーゲー Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
EP4359436A1 (en) 2021-06-22 2024-05-01 Novartis AG Bispecific antibodies for use in treatment of hidradenitis suppurativa
CN113980135B (zh) * 2021-12-27 2022-04-19 三优生物医药(上海)有限公司 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用
WO2023209568A1 (en) * 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU676150B2 (en) 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20030148463A1 (en) * 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
BRPI0617830B8 (pt) 2005-10-26 2021-05-25 Novartis Ag uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo
KR20080109093A (ko) * 2006-04-14 2008-12-16 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
EP2468301A1 (en) 2007-05-29 2012-06-27 Novartis AG New indications for anti-IL-1-beta therapy
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
LT3075858T (lt) 2007-12-21 2020-04-27 Novartis Ag Žinduolių raiškos vektorius
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
KR101734585B1 (ko) 2008-08-28 2017-05-11 노파르티스 아게 정지 코돈 번역초과에 의한 폴리펩티드 이소형의 세포 표면 표시
CN102333871B (zh) 2009-02-27 2013-12-04 诺瓦提斯公司 包含两个选择标记的表达载体***
DK2401383T3 (da) 2009-02-27 2013-12-16 Novartis Ag Fremgangsmåder til udvælgelse af eukaryote celler, som udtrykker et heterologt protein
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CA2827188C (en) 2011-03-17 2020-02-11 Itai Benhar Bi- and monospecific, asymmetric antibodies and methods of generating the same
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
SI2771364T1 (sl) 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
CA2859667C (en) * 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JP2015530245A (ja) 2012-09-26 2015-10-15 スリーエム イノベイティブ プロパティズ カンパニー コーティング可能な組成物、防汚性組成物、防汚性物品、及びこれらを製造する方法
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
RU2015140917A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
ES2701051T3 (es) 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
ES2699599T3 (es) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
US11203631B2 (en) 2013-12-20 2021-12-21 Novartis Ag Eukaryotic cells and methods for recombinantly expressing a product of interest
EP3083677B1 (en) 2013-12-20 2019-08-28 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141378A1 (en) 2015-03-05 2016-09-09 Think Surgical, Inc. Methods for locating and tracking a tool axis
CR20170511A (es) 2015-05-08 2018-01-22 Xencor Inc Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales.
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
KR20180069839A (ko) * 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
EP3515936A1 (en) * 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
PT3443006T (pt) * 2017-03-17 2023-10-26 Sanofi Sa Proteínas de ligação triespecíficas e/ou trivalentes
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos

Also Published As

Publication number Publication date
CO2019013838A2 (es) 2020-05-29
CN110730788A (zh) 2020-01-24
EA201992670A1 (ru) 2020-07-08
AU2018284303A1 (en) 2019-11-07
RU2019140335A3 (es) 2021-10-04
CU20190100A7 (es) 2020-11-30
TWI826377B (zh) 2023-12-21
CA3061097A1 (en) 2018-12-20
JOP20190283A1 (ar) 2019-12-05
JP2022116038A (ja) 2022-08-09
UY37758A (es) 2019-01-31
RU2019140335A (ru) 2021-07-13
KR102633368B1 (ko) 2024-02-06
EP3638692A1 (en) 2020-04-22
JP2020524991A (ja) 2020-08-27
ZA201906757B (en) 2023-03-29
CR20190558A (es) 2020-01-28
WO2018229612A1 (en) 2018-12-20
PE20200384A1 (es) 2020-02-24
SG10201913536TA (en) 2020-02-27
AU2018284303B2 (en) 2021-04-22
MA49394A (fr) 2020-04-22
AR112419A1 (es) 2019-10-30
KR20220167340A (ko) 2022-12-20
AU2021206810A1 (en) 2021-08-12
JP7106234B2 (ja) 2022-07-26
IL271179A (en) 2020-01-30
TW201906864A (zh) 2019-02-16
KR20200005746A (ko) 2020-01-16
US20200308309A1 (en) 2020-10-01
US11987644B2 (en) 2024-05-21
JOP20190283B1 (ar) 2023-09-17
MX2019015021A (es) 2020-02-24
BR112019025904A2 (pt) 2020-06-30
ECSP19087580A (es) 2019-12-27
US20190002589A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
CL2019003613A1 (es) Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
MA55363A (fr) Anticorps multispécifiques egfr x cd28
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
DOP2020000245A (es) Anticuerpos il-11
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
CU24498B1 (es) Anticuerpos de factor xi
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
CR20170200A (es) Conjugados de anticuerpo-farmaco
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение